Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin at -226.7%
Net margin was -226.7% in Q1 FY2026. On a trailing-twelve-month basis it was -465.3%, up 1360.8 pp year over year.
What to watch
Whether net margin reaches the consensus estimate from 2 analysts of -207.8% for the fiscal year ending Dec 2026, up from -819.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -226.7%+65.0 pp QoQ
- Last fiscal yearDec 2025
- -819.6%+997.2 pp YoY
- LTMMar 2026
- -465.3%+1360.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +997.2 pp | +611.8 pp | -385.4 pp |
| 3 years | — | +799.2 pp | — |
| 5 years | +857.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -819.6%
- Year-over-year change
- +997.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -819.6% | +997.2pp |
| FY2024 | 2024-12-31 | -1816.8% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Net Margin vs competitors
How PRLD compares with its peers on the latest reported figures
- PRLD's LTM Mar 2026 net margin of -465.3% is the 4th highest of the 9 companies compared; the peer median is -889.5%.
- Its year-over-year change of +1360.8 pp is the 2nd highest of 7, against a peer median of +67.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -89.6% | +60.0 pp | +16.0 pp | |
| LTM Mar 2026 | -167.0% | +2130.9 pp | +793.9 pp | |
| LTM Mar 2026 | -266.9% | +75.4 pp | +325.9 pp | |
| LTM Mar 2026 | -465.3% | +1360.8 pp | — | |
| LTM Mar 2026 | -589.8% | — | — | |
| LTM Mar 2026 | -1189.1% | +301.7 pp | -609.6 pp | |
| FY2025 | -7587.8% | -5585.1 pp | -7142.2 pp | |
| LTM Mar 2026 | -36891.1% | — | — | |
| LTM Mar 2026 | -143627.1% | -160183.1 pp | -132411.6 pp | |
EPRXEupraxia Pharmaceuticals Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding PRLD) | -889.5% | +67.7 pp | -296.8 pp | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.